Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antibody therapeutics - Xencor

Drug Profile

Research programme: antibody therapeutics - Xencor

Alternative Names: PD1 x costim bispecific antibodies - Xencor; PD1 x costimulation bispecific antibodies - Xencor; XmAb 14484; XmAb 22841; XmAb 23104; XmAb 24306; XmAb 5483; XmAb bispecific x4; XmAb®5485

Latest Information Update: 11 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Xencor
  • Class Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD19 antigen inhibitors; CD20 antigen inhibitors; CD20 antigen modulators; CD3 antigen inhibitors; CD3 antigen modulators; CD38 antigen inhibitors; CD38 antigen modulators; CD40 antigen inhibitors; Cytotoxic T-lymphocyte antigen 4 inhibitors; Fc gamma receptor IIB modulators; Glutamate carboxypeptidase II inhibitors; Interleukin 3 receptor alpha subunit modulators; Interleukin-3 receptor alpha subunit antagonists; Programmed cell death-1 receptor antagonists; Signal transduction pathway inhibitors; Somatostatin receptor 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; B-cell lymphoma; Cancer; Haematological malignancies; Multiple myeloma; Neuroendocrine tumours
  • Research Immunological disorders

Most Recent Events

  • 05 Feb 2019 Xencor and Genentech agree to co-develop XmAb 24306 and other IL-15 cytokine therapeutics worldwide for Cancer
  • 26 Nov 2018 Xencor plans the DUET-3 phase I trial for XmAb23104 for Solid tumours (Late stage disease, Second-line therapy or greater) in the US (IV) in February 2018 (NCT03752398)
  • 05 Nov 2018 Xencor announces intention to submit IND applications for XmAB 24306 in multiple oncology indications in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top